ClinicalTrials.gg
CompletedNCT05411965Updated Jul 27, 2022

A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.

A Phase 1 interventional study of BR3003(T) and BR3003B(R1) in Diabetes Mellitus, Type 2, sponsored by Boryung Pharmaceutical Co., Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-27.

Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Enrollment
88th of 122
48 · median 103
Started
2022
with 2 others
Phase 1
6 of 122
none open now
Registered
113th of 122
by date
Lead sponsor
2 of 122
Boryung Pharmaceutical Co., Ltd

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 88th largest by enrollment, is one of 3 that started in 2022, is one of 6 in phase 1, and was the 113th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To perform a comparative evaluation on the pharmacokinetics and the safety after administration of "BR3003" and co-administration of "BR3003B" and "BR3003C" in healthy adults.

Read the detailed description

A randomized, open-label, single oral dose, two-way crossover study under fasting condition. Target number of subjects: 46 subjects in total.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Diabetes Mellitus
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Those who are 19 years old or older at the screening visit.
  2. Those whose weight is ≥50kg (≥45kg for female subjects) and their (BMI) shall be between 18.0 kg/m2 and 30.0 kg/m2.
  3. Those without congenital or chronic diseases at the screening visit and without any pathological symptom or opinion after an internal medicine examination.
  4. Those who are judged eligible for the trial by the principal investigator (or an authorized trial doctor) according to diagnostic tests such as hematology test, blood chemistry test, serology test and urinalysis that are predefined according to the characteristics of the drugs in addition to results.
  5. Those who agree to rule out the possibility of pregnancy through medically acceptable methods of * used by the subject himself/herself or his/her spouse/partner from the first administration of the investigational drugs to 7 days after the last administration of the investigational drugs, and those who agree not to donate their sperms or eggs.
  6. Those who are given detailed explanations about the trial objectives, components as well as the properties of the investigational drugs and express their voluntary consent to participate in the trial by signing a written consent.

Exclusion criteria

Exclusion Criteria:

  1. Those who currently have or have history of diseases related to digestive system, cardiovascular system, endocrine system, respiratory system, hemato-oncology, infection, kidney and genitourinary system, neuropsychiatric system, musculoskeletal system, immune system, Ear-Nose-Throat system, dermal system, ophthalmologic system, etc.
  2. Those who have medical history of gastrointestinal resection (however, appendectomy and hernia operation shall be excluded) or gastrointestinal system diseases that may influence the absorption of drugs.
  3. Those who took drugs that substantially induce or inhibit drug-metabolizing enzymes of barbiturates, etc. in 30 days prior to the first administration or who took drugs that can impact the study in 10 days before the first administration. (However, subjects may participate in the study as judged by the principal investigator (or an authorized trial doctor) in consideration of pharmacokinetic or pharmacodynamic characteristics such as the interaction with the drugs and half-life of co-administered drugs.)
  4. Those who have participated in a bioequivalence study or other clinical trials and have been administered with investigational drugs in 180 days prior to the first administration. (The day of the last administration of investigational drugs shall be counted as day 1 of the end of trial.)
  5. Those who have given a whole blood donation in 60 days prior to the first administration, who have given an apheresis blood donation in 14 days prior to the first administration or who have received blood transfusion in 30 days prior to the first administration.
  6. Those who are applicable to the following conditions in 30 days prior to the first administration:

    • Male subjects: average alcohol intake > 21 units/week
    • Female subjects: average alcohol intake > 14 units/week

      (1 unit= 50 mL of soju, 30 mL of hard liquor or 250 mL of beer)

    • Daily average smoking of >20 cigarettes
  7. Those who apply to the following criteria

    • Those who have medical history of to major ingredients, other ingredients or additives of the investigational drugs.
    • Those who have diabetic ketoacidosis, diabetic coma and precoma or type 1 diabetes.
    • Those who are under dialysis.
    • Those who currently have or have medical history of heart failure.
    • Those who have active bladder cancer or have history of bladder cancer.
    • Those who have hepatopathy or severe renal impairment.
    • Those who have severe infection or severe trauma before or after surgery.
    • Those who have uninvestigated, gross hematuria.
    • Those who have genetic problems including galactose intolerance, Lapp lactase deficiency and glucose-galactose malabsorption.
    • Those whose is \< 60 mL/min/1.73 m2.
  8. Others who are judged ineligible to participate in the trial by the principal investigator (or an authorized trial doctor) due to reasons other than the above inclusion/exclusion criteria.
  9. Female volunteers who are pregnant, suspected to be pregnant or breastfeeding.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Sequence Group A

    The investigational products will be administered according to the treatment groups assigned to each sequence group in Period 1 and Period 2. \*Sequence A \[Period 1\] Co-administration of BR3003B(R1) and BR3003C(R2) (single dose) - Wash out for 7 days \[Period 2\] Administration of BR3003(T) (single dose)

    Drug: BR3003(T) · Drug: BR3003B(R1) · Drug: BR3003C(R2)

  • Experimental
    Sequence Group B

    The investigational products will be administered according to the treatment groups assigned to each sequence group in Period 1 and Period 2. \*Sequence B \[Period 1\] Administration of BR3003(T) (single dose) - Wash out for 7 days \[Period 2\] Co-administration of BR3003B(R1) and BR3003C(R2) (single dose)

    Drug: BR3003(T) · Drug: BR3003B(R1) · Drug: BR3003C(R2)

Interventions

  • DrugBR3003(T)

    Test drug (T):"BR3003" Boryung Pharmaceutical Co., Ltd.

    Also known as: Dapagliflozin 10mg / Pioglitazone 30mg

  • Reference drug 1 (R1): "BR3003B" of Celltrion Pharm, Inc.

    Also known as: Pioglitazone 30mg

  • Reference drug 2 (R2): "BR3003C" of AstraZeneca Korea

    Also known as: Dapagliflozin 10mg

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic variables - AUC

    Area under the plasma concentration versus time curve(AUCt) of Pioglitazone and Dapagliflozin(Blood samples are collected 22 times for each Period.)

    Time frame: Pre-dose(0hour), 0.167hour(10 min), 0.333hour(20 min), 0.5hour(30 minutes), 0.667hour(40min), 1hour, 1.5hour, 2hour, 3hour, 4hour, 5hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour

  2. Pharmacokinetic variables - Cmax

    Peak Plasma Concentration(Cmax) of Pioglitazone and Dapagliflozin(Blood samples are collected 22 times for each Period.)

    Time frame: Pre-dose(0hour), 0.167hour(10 min), 0.333hour(20 min), 0.5hour(30 minutes), 0.667hour(40min), 1hour, 1.5hour, 2hour, 3hour, 4hour, 5hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour

Secondary outcomes

  1. Pharmacokinetic variables - AUC∞

    AUC∞ of Pioglitazone and Dapagliflozin (Blood samples are collected 22 times for each Period.)

    Time frame: Pre-dose (0hour), 0.167hour (10min), 0.333hour (20 min), 0.5hour (30 min), 0.667hour (40min), 1hour, 1.5hour, 2hour, 3hour, 4hour, 5hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour

  2. Pharmacokinetic variables - AUCt/AUC∞

    AUCt/AUC∞ of Pioglitazone and Dapagliflozin (Blood samples are collected 22 times for each Period.)

    Time frame: Pre-dose (0hour), 2hour, 4hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour

  3. Pharmacokinetic variables - Tmax

    Tmax of Pioglitazone and Dapagliflozin (Blood samples are collected 22 times for eachour Period.)

    Time frame: Pre-dose (0hour), 0.167hour (10min), 0.333hour (20 min), 0.5hour (30 min), 0.667hour (40min), 1hour, 1.5hour, 2hour, 3hour, 4hour, 5hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour

  4. Pharmacokinetic variables - t1/2

    t1/2 of Pioglitazone and Dapagliflozin (Blood samples are collected 22 times for eachour Period.)

    Time frame: Pre-dose (0hour), 0.167hour (10min), 0.333hour (20 min), 0.5hour (30 min), 0.667hour (40min), 1hour, 1.5hour, 2hour, 3hour, 4hour, 5hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour

  5. Pharmacokinetic variables - AUCt of Pioglitazone M-IV

    AUCt of Pioglitazone M-IV (Blood samples are collected 14 times for eachour Period.)

    Time frame: Pre-dose (0hour), 2hour, 4hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour

  6. Pharmacokinetic variables - Cmax of Pioglitazone M-IV

    Cmax of Pioglitazone M-IV (Blood samples are collected 14 times for eachour Period.)

    Time frame: Pre-dose (0hour), 2hour, 4hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour

  7. Pharmacokinetic variables - AUC∞ of Pioglitazone M-IV

    AUC∞ of Pioglitazone M-IV (Blood samples are collected 14 times for eachour Period.)

    Time frame: Pre-dose (0hour), 2hour, 4hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour

  8. Pharmacokinetic variables - AUCt/AUC∞ of Pioglitazone M-IV

    AUCt/AUC∞ of Pioglitazone M-IV (Blood samples are collected 14 times for eachour Period.)

    Time frame: Pre-dose (0hour), 2hour, 4hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour

  9. Pharmacokinetic variables - Tmax of Pioglitazone M-IV

    Tmax of Pioglitazone M-IV (Blood samples are collected 14 times for eachour Period.)

    Time frame: Pre-dose (0hour), 2hour, 4hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour

  10. Pharmacokinetic variables - t1/2 of Pioglitazone M-IV

    t1/2 of Pioglitazone M-IV (Blood samples are collected 14 times for eachour Period.)

    Time frame: Pre-dose (0hour), 2hour, 4hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour

07

Study locations

1 site
  • Clinical Research Center, H PLUS Yangji Hospital
    Seoul, Gwanakgu 08779, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jul 2022, 2 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 2 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2022
First posted
Jun 9, 2022
StartActual
Apr 28, 2022
Primary completionActual
Jul 3, 2022
CompletionActual
Jul 3, 2022
Last update
Jul 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05411965
Responsible party
Sponsor
First posted
Jun 9, 2022
Start date
Apr 28, 2022
Primary completion
Jul 3, 2022
Completion
Jul 3, 2022
Last update
Jul 27, 2022

Study contacts

Jaewoo Kim
principal investigator · H Plus Yangji Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Dapagliflozin

Start the discussion